Pfizer

Health Care Pharmaceuticals New York City, New York Last filing Feb 26, 2026 · FY2025

                    Revenue
                    FY2025
                
$62.6B
                    3y CAGR -12.0%
                    
                    P3
                    
                    -1.6%
                    
                    Net income
                    FY2025
                
$7.8B
                    Net margin +12.4%
                    
                    P53
                    
                    -3.2%
                    
                    Total assets
                    FY2025
                
$208.2B
                    ROA +3.7%
                    
                    P30
                    
                    -2.5%
                    
                    Operating cash flow
                    FY2025
                
$11.7B
                    FCF margin +14.5%
                    
                    P49
                    
                    -8.2%

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

31 accounts · 3 years

Total assets $208.2B

Total liabilities $121.4B

Shareholders equity $86.5B

Account	2025	2024	2023
Assets
Cash and Cash Equivalents	1.8%	1.6%	5.6%
Short Term Investments	14.7%	17.1%	8.6%
Accounts Receivable	19.0%	18.0%	22.0%
Inventory	17.0%	17.1%	20.0%
Prepaid Expenses	4.5%	6.7%	10.4%
Other Current Assets	4.5%	6.7%	10.4%
Total Current Assets	68.6%	79.1%	85.1%
Property,Plant and Equipment	30.9%	28.9%	37.2%
Goodwill	113.9%	107.7%	133.1%
Intangible Assets	85.9%	87.1%	127.5%
Long Term Investments	2.6%	3.5%	30.2%
Other Noncurrent Assets	15.4%	15.4%	24.5%
Total Assets	332.6%	335.4%	444.9%
Liabilities
Accounts Payable	8.4%	8.9%	13.2%
Accrued Liabilities	9.7%	9.9%	10.1%
Current Portion of Long Term Debt	4.8%	5.9%	4.4%
Other Current Liabilities	29.8%	31.0%	40.3%
Total Current Liabilities	59.1%	67.6%	93.9%
Long Term Debt	98.5%	90.2%	120.9%
Deferred Tax Liabilities	3.8%	3.3%	1.3%
Other Noncurrent Liabilities	23.5%	22.2%	32.5%
Total Liabilities	194.0%	196.3%	269.5%
Equity
Preferred Stock	0.0%	0.0%	0.1%
Common Stock	0.8%	0.8%	0.9%
Additional Paid In Capital	151.0%	147.1%	181.9%
Retained Earnings	183.1%	183.5%	232.5%
Treasury Stock	183.8%	180.4%	224.9%
Accumulated Other Comprehensive Income	-12.9%	-12.3%	-15.6%
Noncontrolling Interest	0.5%	0.5%	0.5%
Total Stockholders Equity	138.2%	138.6%	174.8%
Total Liabilitiesand Equity	332.6%	335.4%	444.9%

Income Statement

Revenue, expense, and profitability

19 accounts · 3 years

Revenue $62.6B

Operating income $7.8B

Net income $7.8B

Account	2025	2024	2023
IncomeStatement
Revenues Total Revenue	100.0%	100.0%	100.0%
Expenses Cost of Revenue	25.7%	28.1%	49.0%
Expenses Research and Development	16.7%	17.0%	21.0%
Expenses Selling,General and Administrative	22.0%	23.2%	29.0%
Expenses Depreciation and Amortization	10.5%	11.0%	12.4%
Expenses Share Based Compensation	1.3%	1.4%	1.0%
Expenses Restructuring and Asset Impairment	1.7%	3.1%	3.9%
Other Income Expense Operating Income	12.4%	12.6%	4.2%
Other Income Expense Interest Income	1.0%	0.9%	3.2%
Other Income Expense Interest Expense	4.3%	4.9%	4.3%
Other Income Expense Other Income/expense	-10.7%	-6.9%	-0.4%
Other Income Expense Income Before Tax	12.0%	12.6%	2.1%
Income Tax Income Tax Expense	-0.4%	-0.0%	-2.2%
net Income net Income	12.4%	12.6%	4.2%
net Income Comprehensive Income	12.1%	12.8%	4.8%
Earnings Per Share Basic Eps	0.0%	0.0%	0.0%
Earnings Per Share Diluted Eps	0.0%	0.0%	0.0%
Earnings Per Share Weighted Average Shares Basic	9.1%	8.9%	11.1%
Earnings Per Share Weighted Average Shares Diluted	9.1%	9.0%	11.2%

Cash Flow Statement

Operating, investing, and financing flows

22 accounts · 3 years

Operating cash flow $11.7B

Investing cash flow $-1.4B

Financing cash flow $-10.3B

Account	2025	2024	2023
CashFlow
Operating Activities net Income	12.4%	12.6%	4.2%
Operating Activities Depreciation and Amortization	10.5%	11.0%	12.4%
Operating Activities Stock Based Compensation	1.3%	1.4%	1.0%
Operating Activities Deferred Income Taxes	-3.4%	-3.3%	-6.8%
Operating Activities Changes In Operating Assets and Liabilities	-0.5%	1.5%	1.6%
Operating Activities Other Non Cash Items	-5.9%	-4.9%	1.2%
Operating Activities net Cash From Operating Activities	18.7%	20.0%	17.1%
Investing Activities Capital Expenditures	4.2%	4.6%	7.7%
Investing Activities Business Acquisitions	11.1%	0.0%	85.3%
Investing Activities Purchases of Investments	0.5%	0.3%	0.4%
Investing Activities Other Investing Activities	-0.3%	-0.0%	0.4%
Investing Activities net Cash From Investing Activities	-2.2%	4.2%	-63.4%
Financing Activities Proceeds From Debt	15.5%	0.0%	60.6%
Financing Activities Repayment of Debt	10.8%	3.5%	5.0%
Financing Activities Repurchase of Common Stock	0.0%	0.0%	0.0%
Financing Activities Dividends Paid	15.6%	15.1%	18.3%
Financing Activities Other Financing Activities	-0.7%	-0.7%	-1.2%
Financing Activities net Cash From Financing Activities	-16.5%	-26.9%	51.2%
Cash Reconciliation Effect of Exchange Rate On Cash	0.1%	-0.1%	-0.1%
Cash Reconciliation net Change In Cash	0.1%	-2.8%	4.8%
Cash Reconciliation Cash At Beginning of Period	1.9%	1.7%	5.7%
Cash Reconciliation Cash At End of Period	1.9%	1.7%	5.7%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 3 years

Ratio	2025	2024	2023
Profitability
Gross margin	+74.3%	+71.9%	+51.0%
Operating margin	+12.4%	+12.6%	+4.2%
Net margin	+12.4%	+12.6%	+4.2%
FCF margin	+14.5%	+15.5%	+9.4%
Growth
Revenue CAGR (3y)	-12.0%	-4.8%	+6.9%
Returns
ROE	+9.0%	+9.1%	+2.4%
ROA	+3.7%	+3.8%	+0.9%
ROIC	+5.2%	+5.4%	+1.4%
Liquidity
Current ratio	1.16x	1.17x	0.91x
Quick ratio	0.35x	0.29x	0.29x
Leverage
D/E	1.40x	1.42x	1.54x
Interest coverage	2.91x	2.60x	0.96x
Efficiency
Asset turnover	0.30x	0.30x	0.22x
Cash conversion cycle	+192d	+172d	+131d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Pfizer

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history